HERON THERAPEUTICS INC (HRTX)
US4277461020 - Common Stock
Taking everything into account, HRTX scores 2 out of 10 in our fundamental rating. HRTX was compared to 564 industry peers in the Biotechnology industry. Both the profitability and financial health of HRTX have multiple concerns. While showing a medium growth rate, HRTX is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year HRTX has reported negative net income.
In the past year HRTX has reported a negative cash flow from operations.
In the past 5 years HRTX always reported negative net income.
In the past 5 years HRTX always reported negative operating cash flow.
1.2 Ratios
With a decent Return On Assets value of -22.06%, HRTX is doing good in the industry, outperforming 77.62% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.06% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-64.8%
ROA(5y)-59.72%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 65.50%, HRTX belongs to the best of the industry, outperforming 82.24% of the companies in the same industry.
HRTX's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for HRTX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 65.5% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.24%
GM growth 5Y-5.45%
2. Health
2.1 Basic Checks
HRTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
HRTX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, HRTX has more shares outstanding
HRTX has a worse debt/assets ratio than last year.
2.2 Solvency
HRTX has an Altman-Z score of -11.15. This is a bad value and indicates that HRTX is not financially healthy and even has some risk of bankruptcy.
HRTX has a Altman-Z score of -11.15. This is in the lower half of the industry: HRTX underperforms 78.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -11.15 |
ROIC/WACCN/A
WACC9.42%
2.3 Liquidity
A Current Ratio of 2.38 indicates that HRTX has no problem at all paying its short term obligations.
HRTX has a Current ratio of 2.38. This is in the lower half of the industry: HRTX underperforms 72.82% of its industry peers.
HRTX has a Quick Ratio of 1.85. This is a normal value and indicates that HRTX is financially healthy and should not expect problems in meeting its short term obligations.
HRTX has a worse Quick ratio (1.85) than 77.98% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.38 | ||
| Quick Ratio | 1.85 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 72.65% over the past year.
Looking at the last year, HRTX shows a quite strong growth in Revenue. The Revenue has grown by 15.59% in the last year.
HRTX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.39% yearly.
EPS 1Y (TTM)72.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%82.86%
Revenue 1Y (TTM)15.59%
Revenue growth 3Y12.76%
Revenue growth 5Y10.39%
Sales Q2Q%13.42%
3.2 Future
The Earnings Per Share is expected to grow by 21.92% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 18.92% on average over the next years. This is quite good.
EPS Next Y86.36%
EPS Next 2Y41.7%
EPS Next 3Y31.3%
EPS Next 5Y21.92%
Revenue Next Year19.2%
Revenue Next 2Y20.39%
Revenue Next 3Y20.78%
Revenue Next 5Y18.92%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for HRTX. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 258.53, which means the current valuation is very expensive for HRTX.
Compared to the rest of the industry, the Price/Forward Earnings ratio of HRTX indicates a rather cheap valuation: HRTX is cheaper than 91.12% of the companies listed in the same industry.
HRTX is valuated expensively when we compare the Price/Forward Earnings ratio to 23.23, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 258.53 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
HRTX's earnings are expected to grow with 31.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.7%
EPS Next 3Y31.3%
5. Dividend
5.1 Amount
No dividends for HRTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
HERON THERAPEUTICS INC
NASDAQ:HRTX (11/1/2024, 8:07:37 PM)
After market: 1.74 -0.04 (-2.25%)1.78
+0.04 (+2.3%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap269.97M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 258.53 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.06% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 65.5% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.38 | ||
| Quick Ratio | 1.85 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)72.65%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y86.36%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)15.59%
Revenue growth 3Y12.76%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y